Current Research Studies

Phase 1 Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 (CC-90010) in Pediatric Cancer

SC-4019

What is the goal of the study?

This is an open-label, multicenter, pediatric, dose escalation and expansion phase 1 clinical trial of two BET inhibitors, assessed in two separate arms, each with two cohorts. Arm 1 will investigate BMS-986158 in patients with relapsed or refractory solid tumors or lymphoma. Within Arm 1, Cohort 1A will consist of patients with unselected relapsed or refractory solid tumors or lymphoma, while Cohort 1B will consist of patients with relapsed or refractory solid tumors or lymphoma that have defined molecular features predicted to increase sensitivity to BET inhibition. Arm 2 will investigate a blood brain barrier penetrant BET inhibitor, BMS-986378 (CC-90010), in patients with relapsed or refractory CNS tumors / CNS metastatic disease. Within Arm 2, Cohort 2A will consist of patients with unselected relapsed or refractory CNS tumors, while Cohort 2B will consist of patients with relapsed or refractory CNS tumors that have defined molecular features predicted to increase sensitivity to BET inhibition

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: